Tom Williams/Vaccine

Coverage and timeliness of vaccination and the validity of routine estimates: Insights from a vaccine registry in Kenya.Adetifa IMO, Karia B, Mutuku A, Bwanaali T, Makumi A, Wafula J, Chome M, Mwatsuma P, Bauni E, Hammitt LL, Mataza C, Tabu C, Kamau T, Williams TN, Scott JAG
Vaccine, (2018). 36:7965-7974

High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, Mwangi TW, Marsh K
Vaccine, (2006). 24:4233-46

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwambingu G, Lowe B, Conway DJ, Marsh K
Vaccine, (2004). 23:718-28